AVN 576 | 1354566-03-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: AVN 576
• 英文别名: (R)-4-([1,4'-bipiperidin]-1'-yl)-2-((2R,3S)-2-((E)-3-iodostyryl)-4-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)azetidin-1-yl)-4-oxo-N-((R)-1-phenylethyl)butanamide；(2R)-2-[(2R,3S)-2-[(E)-2-(3-iodophenyl)ethenyl]-4-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]azetidin-1-yl]-4-oxo-N-[(1R)-1-phenylethyl]-4-(4-piperidin-1-ylpiperidin-1-yl)butanamide
• CAS: 1354566-03-2
• 化学式: C₄₂H₄₈IN₅O₅
• 分子量: 829.778
• InChiKey: VBXHSGJTMUBAJO-AFAPVMNMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  53
• 可旋转键数：
  11
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(4(S)-phenyloxazolidin-2-on-3-yl)acetyl chloride 在 甲酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 22.0h， 生成 AVN 576
  参考文献：
  名称：

  Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging

  摘要：

  SRX246 is a potent, highly selective human vasopressin V1a antagonist that crosses the blood-brain barrier in rats. CNS penetration makes SRX246 an ideal candidate for potential radiolabeling and use in visualization and characterization of the role of the V1a receptor in multiple stress-related disorders. Before radiolabeling studies, cold reference analogs of SRX246 were prepared. This study describes the synthesis and in vitro screening for human V1a receptor binding and permeability of fluoro, iodo, and methyl reference compounds for SRX246 and the preparation of a tin precursor. For each compound, the potential utility of corresponding radiolabeled analogs for PET and SPECT imaging is discussed. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.013

文献信息

• Compositions and methods for treating neurodegenerative diseases
  申请人：Azevan Pharmaceuticals, Inc.

  公开号：US10364236B2

  公开（公告）日：2019-07-30

  Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.

  本文描述了用于治疗神经退行性疾病和失调的化合物及其组合物、方法和用途。特别是，本文描述了血管加压素受体调节剂及其组合物、方法和用途，用于治疗亨廷顿氏病、帕金森氏病和阿尔茨海默氏症等神经退行性疾病的神经精神方面。
• COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER
  申请人：Azevan Pharmaceuticals, Inc.

  公开号：EP3351104B1

  公开（公告）日：2020-12-09
• COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY
  申请人：Azevan Pharmaceuticals, Inc.

  公开号：US20200276167A1

  公开（公告）日：2020-09-03

  Compounds, and compositions, methods, and uses thereof, are described herein for treating brain injuries.
• US9802925B2
  申请人：——

  公开号：US9802925B2

  公开（公告）日：2017-10-31
• Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging
  作者：Karine Fabio、Christophe Guillon、Carl J. Lacey、Shi-fang Lu、Ned D. Heindel、Craig F. Ferris、Michael Placzek、Graham Jones、Michael J. Brownstein、Neal G. Simon

  DOI：10.1016/j.bmc.2011.12.013

  日期：2012.2

  SRX246 is a potent, highly selective human vasopressin V1a antagonist that crosses the blood-brain barrier in rats. CNS penetration makes SRX246 an ideal candidate for potential radiolabeling and use in visualization and characterization of the role of the V1a receptor in multiple stress-related disorders. Before radiolabeling studies, cold reference analogs of SRX246 were prepared. This study describes the synthesis and in vitro screening for human V1a receptor binding and permeability of fluoro, iodo, and methyl reference compounds for SRX246 and the preparation of a tin precursor. For each compound, the potential utility of corresponding radiolabeled analogs for PET and SPECT imaging is discussed. (C) 2011 Elsevier Ltd. All rights reserved.